CSL Behring Launches New Gene Therapy Information Site for Patients and Families

CSL Behring's Commitment to Gene Therapy Education

On July 22, 2025, CSL Behring announced the launch of its informative website, the 'Gene Therapy Portal,' designed to enhance the understanding and accessibility of gene therapy information for patients and their families. The website can be found at Gene Therapy Portal.

Gene therapy has gained significant attention as a groundbreaking medical option over recent years, especially in the treatment of rare diseases. However, there remains a notable gap in the availability of reliable and understandable information regarding its mechanisms, efficacy, and safety for the general public. This is where CSL Behring aims to bridge the gap.

The Gene Therapy Portal presents information under the concept of "A Future Starts with Knowledge," featuring five main categories:
1. What is a Gene?
2. What is Gene Therapy?
3. Types of Gene Therapy
4. Shared Decision Making: A collaborative approach between patients and healthcare providers
5. Additional Resources: Reference materials, related links, and more.

Each section provides clear and concise explanations of technical content to ensure that visitors understand the complexities of gene therapy. Additionally, video content is included to further enhance the educational experience and to facilitate deeper comprehension.

As a global biotechnology company specializing in innovative therapies for rare diseases, CSL Behring recognizes its responsibility to disseminate accurate and trustworthy medical information. The creation of the Gene Therapy Portal is a testament to this commitment, as it seeks to empower patients and their families to make informed medical decisions based on a thorough understanding of gene therapy.

The site has been developed in collaboration with leading experts in the field. Dr. Yoshikazu Yonemitsu, a professor at Kyushu University's Graduate School of Pharmaceutical Sciences, serves as a supervising physician. Meanwhile, Professor Takeo Nakayama from Kyoto University's Graduate School of Medicine oversees the shared decision-making component.

CSL Behring Company Overview:
CSL Behring is dedicated to developing and delivering innovative medicines for treating severe and rare diseases. Based in Tokyo, Japan, its primary areas of focus include immunology, rare diseases, and bleeding disorders like hemophilia. Established two decades ago, CSL Behring has steadily progressed to enhance the quality of life for patients. The company pledges to continue contributing to improvements in healthcare frameworks in Japan and around the world.

For more information about CSL Behring and its offerings, please visit CSL Behring Japan.

About CSL

CSL Limited, listed on the Australian Stock Exchange (ASX: CSL) and the US Over-The-Counter listings (USOTC: CSLLY), is a global biotechnology company with an extensive portfolio of life-saving medications, including treatments for hemophilia, immunodeficiency syndromes, influenza vaccines, and medications for iron deficiency and kidney-related diseases. Since its founding in 1916, CSL has harnessed the latest technology to deliver on its promise of saving lives. Combining operational excellence, a strong focus on research and development, and a dedicated workforce of 32,000 employees, CSL operates in over 100 countries to support patients in need.

For further insights into the future of biotechnology, please visit CSL Behring Vita and follow us on Twitter at @CSL. For more information, visit the main site at CSL Global.